Small Cap Feast
Small Cap Feast – 18th August 2016
Dish of the Day:
No primary today
No primary today
Off the Menu:
Marwyn Management Partners (MMP) has delisted from AIM NewRiver Retail (NRR.L) is leaving AIM to join the Main Market as a REIT
Marwyn Management Partners (MMP) has delisted from AIM
NewRiver Retail (NRR.L) is leaving AIM to join the Main Market as a REIT
What’s Cooking in the IPO Kitchen?
LoopUp—The provider of conference calls and online meetings is seeking to join AIM. 2015 revs of £9.2m and EBITDA of £1.02m
Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap
Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September
Autins Group plc – The acoustic and thermal insulation specialist now looks to join AIM late August
Physiomics* (PYC.L) 0.04p £1.22m
The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials has signed a share purchase agreement to acquire BioMoti whose platform technology, Oncojan™, creates nanoparticles which package cancer drugs into sustained release delivery vehicles which are then coated with tumour targeting protein called CD95R. There are lots of synergies here. The deal is contingent on a £1m placing.
Tricor (TRIC.L) 0.4p £0.74m
Tricor which is a ‘Rule 15’ investing company has been informed that the Upper Tribunal (Tax and Chancery Chamber) has rejected the Company’s appeal to reclaim £1,847,976.70 of input VAT plus any interest and costs. The Company has until 2 September 2016 to make any application for permission to make a further appeal to the Court of Appeal in England & Wales. The Company is considering the implications of the decision with its lawyers and is awaiting further advice from them. There is also an unquantified prospective liability for costs incurred.
Concepta (CPT.L) 11.87p £13m
The UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women’s fertility has announced H1Jun16 results. All Oil & Gas assets disposed or dissolved. Concepta acquired post year end for £3m. Cash balance at the period end was $1.335m . ‘MyLotus’ to launch in China this year and targeting UK/Europe launch in 2017 subsequent to CE Marking.
Akers Biosciences (AKRL) 235p £12.8m
The developer of rapid health information technologies, announces the results of a study of the Company’s BreathScan OxiChek™ test, the first disposable breath test to rapidly determine levels of oxidative stress in the body – an indicator of the overall health and wellbeing of a person. The study has demonstrated an exceptionally high correlation between an Akers Bio rapid breath test and an established reference laboratory blood test. FDA clearance not required and already being marketed.
Rex Bionics (RXB.L) 32.5p £8.3m
The pioneer of the REX Robot technology that enhances the mobility of wheelchair users, has announced positive results from a second interim analysis of its RAPPER II clinical trial showing that REX can safely be used by people with spinal cord injury. 51 out of 53 volunteers (96%) were able to complete the transfer-walk-exercise protocol (“Treatment Success”) – the primary endpoint of the trial. There were no Serious Adverse Events.
Empresaria Group (EMR.L) 98p £48m
H1Jun16 results from the international specialist staffing group. Net fee income +9% to £27.2m, adjusted EPS +26% to 4.3p. No interim dividend (traditionally only pays final). Average net debt of £10.5m was up 14% on prior year, due to the investment spend in the period of £3.4m. Continues to look for suitable external investments to fill in gaps in sector or geographic coverage with a pipeline of interesting prospects. 8.5xPE and 1.1% yield.
YOLO Leisure & Tech (YOLO.L) 0.9p £1.6m
The company focusing on opportunities in the travel, technology and leisure sectors, announced that, TVPlayer Limited, in which YOLO has an interest by virtue of its investment into TVPlayer’s parent company Simplestream Limited, has signed a multi-year agreement with Viacom International Media Networks to simulcast a selection of its pay-TV channels on TVPlayer Plus, TVPlayer’s low cost subscription TV service.
Nostra Terra Oil and Gas (NTOG.L) 1.85p £1.75m
Further to the recent announcements by the Company concerning the sale of its interest in the Chisholm Trail Prospect, the Company has announced the US$2.1 million sale has completed successfully. Nostra Terra intends to deploy the net proceeds from the Sale to accelerate its growth plans and for general working capital purposes. Nostra Terra continues to evaluate a number of opportunities across different geographic regions, particularly North America and Egypt.
EG Solutions (EGS.L) 44p £9.98m
The back office workforce optimisation company, has announced that its partner Aspect Software Inc. has closed a three-year contract with a leading social networking corporation (‘the Client’) to supply eg’s back office optimisation software. The initial contract is valued at US$1 million with up to 4,000 licences being deployed over the next 3 years. FYJAN17 forecasts suggest a 19.1x PE multiple falling to 8.7x the following year.
HydroDec Group (HYR.L) 3.25p £26.1m
The specialist re-refiner of industrial oils reports that its Australian operation has been awarded a 5 year contract for the supply of inhibited transformer and switchgear oil by Essential Energy, a major Australian utility. The contract includes the collection and re-refining of all generated PCB (polychlorinated biphenyl) and non-PCB waste oils and is expected to generate over 1 million litres of new transformer oil sales over the life of the contract. FY16E forecasts suggest £36.7 m revenues and a loss per share of 0.49p.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.